Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.69 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30184878 | 1.00 | AR (0.69) | ARNR3C1HDAC1 | |
| SCHEMBL1715104 | 0.90 | AR (0.69) | ARNR3C1HDAC1 | |
| SCHEMBL30184903 | 0.90 | AR (0.69) | ARNR3C1HDAC1 | |
| SCHEMBL20003450 | 0.90 | AR (0.55) | ARNR3C1HDAC1 | |
| SCHEMBL16564502 | 0.89 | AR (0.68) | ARNR3C1 | |
| SCHEMBL21788615 | 0.89 | AR (0.81) | ARNR3C1 | |
| SCHEMBL1716398 | 0.87 | AR (0.74) | ARNR3C1HDAC1 | |
| SCHEMBL30377977 | 0.87 | AR (0.66) | ARNR3C1HDAC1 | |
| SCHEMBL1715704 | 0.87 | AR (0.66) | ARNR3C1HDAC1 | |
| SCHEMBL547013 | 0.86 | AR (0.69) | ARNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-3970721-A1 | DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | US | disclosed |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-07-11 | — | — | US | disclosed |
| US-20180086718-A1 | Diarylhydantoin Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-03-29 | — | — | US | disclosed |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-07-08 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709517-B2 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-05-04 | — | — | US | disclosed |
| EP-1893196-A4 | DIARYLHYDANTOIN COMPOUNDS | UNIV CALIFORNIA (US) | 2009-03-18 | — | — | EP | disclosed |
| EP-1893196-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006124118-A1 | DIARYLHYDANTOIN COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132452-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
| US-20180086718-A1 | Diarylhydantoin Compounds | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
| US-20070004753-A1 | N-methyl-4-{4-[7-(4-cyano-3 -trifluoromethylphenyl)-6,8-dioxo-5,7-diazaspiro[3.4]oct-5-yl]-phenyl}butyramide; for treatment of hormone refractory prostate cancer | AR, BRDT, GNRHR | AR 1/4885NR3C1 263/4885HDAC1 176/4885 |
| US-20100172975-A1 | TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS | CDK4, CCNH, VHL | AR 113/4885NR3C1 1031/4885HDAC1 952/4885 |
| US-20250333385-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
| US-20190210974-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
| US-20200079741-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
| US-20230109968-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
| US-20210238145-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
| US-20100210665-A1 | DIARYLHYDANTOIN COMPOUNDS | BPHL, AR, SHBG | AR 2/4885NR3C1 765/4885HDAC1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.